Cancer - Prostate(구연) (NP-040) 임상 환경에서 PSA <2.5ng/ml인 환자군의 전립선 조직검사전 전립선 MRI의 필요성 고찰 성균관의대 삼성서울병원 최중원, 강민용, 성현환, 정병창, 서성일, 전성수, 이현무, 전황균 Multiparametric MRI (mpMRI) and prostate biopsy may be performed in PSA < 2.5ng/ml for reasons such as hematospermia in clinical setting. In these patients, we wanted to find out the clinically significant prostate cancer (csCaP) detection rate and establish the clinical efficacy. 572 patients conducted mpMRI with PSA < 2.5 ng/ml from January 2016 to December 2018. Among them, 207 patients who underwent mpMRI in clinical setting were included. 365 patients were excluded who take mpMRI in a routine health screening. Finally, 41 patients who performed prostate biopsy were included in the analysis. Patient's biopsy reasons and mpMRI findings were investigated. Also, their biopsy method and outcome differences were evaluated. The average age of patients who performed prostate biopsy was 60.6 ± 7.4 years, 1.6 ± 0.6 ng/ml for PSA and 33.9 ± 15.2 g for prostate volume. The PI-RADs score in the mpMRI was 10 (24.4%), 29 (70.7%), and 2 (4.9%) in the order ≤3, 4 and 5, respectively. Most frequent reason of biopsy for patients with PSA < 2.5ng/ml was the TRUS abnormal echogenicity (29.3%) (Fig.1). The csCaP detection rate was 0%, 15%, and 8% respectively in systematic, targeted, and combination biopsies (p=0.7047). Overall, the detection rate of csCaP was 9.8% (n = 4/41) when prostate biopsies were performed for definite lesion, and 1.9% (n = 4/207) in total patients. The csCaP detection rate was considerable in the PSA <2.5ng/dl cases who performed mpMRI. And if lesions are clearly observed in mpMRI, it is recommended that only targeted biopsies be implemented. keywords : Prostate biopsy, PSA, screening